门冬酰胺酶制剂治疗淋巴系统恶性肿瘤耐药机制的研究进展
被引量：2
摘要
左旋门冬酰胺酶是淋巴系统恶性肿瘤治疗中的重要组成药物，因其生物学来源不同，其药代动力学特征也存在不同。本文将对门冬酰胺酶不同制剂进行比较并对其在淋巴系统恶性肿瘤治疗中的耐药机制作一综述。
出处
《国际输血及血液学杂志》
CAS
2007年第5期444-446,共3页
International Journal of Blood Transfusion and Hematology
参考文献15
-
1Graham ML. Pegaspargase:a review of clinical studies. Advanced Drug Delivery Reviews,2003,55(10) : 1293-1302.
-
2Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol, 1999, 457:621-629.
-
3Albertsen BK, Schrtader H, Ingerslev J, et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematology, 2001,115(4) :983-990.
-
4Kwok CS, Kham SK, Ariffin H,et al. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli- asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer, 2006, 47 (3) :299-304.
-
5Hawkins DS, Park JR, Thomson BG, et al. Asparaginase Pharmacokinetics After Intensive Polyethylene Glycol-Conjugated L-Asparaginase Therapy for Children with Relapsed Acute Lymphoblastic Leukemia. Clin Cancer Res, 2004,10 (15) : 5335- 5341.
-
6Avramis VI, Sencer S, Periclou AP , et al. Arandomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia : a Children's Cancer Group study. Blood, 2002,99 (6) : 1986-1994.
-
7Abshire TC, Pollock BH, Billett AL,et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric ontology group study. Blood, 2000,96 (5) : 1709-1715.
-
8Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia, haematologica, 2006, 91(1):24-31.
-
9Avramis VI, Panosyan EH. Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations: The Past, the Present and Recommendations for the Future. Clinical Pharmacokinetics,2005, 44(4) : 367-393.
-
10Appel IM, den Boer ML, Meijerink JP,et al. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood, 2006,107(11) : 4244-4249.
同被引文献15
-
1朱金武,关勇彪.紫杉醇诱导的人白血病CCRF-CEM多药耐药细胞模型的建立[J].中国药理学与毒理学杂志,2010,24(2):134-139. 被引量：3
-
2张立阳,赵玉沛,吴元德,廖泉,郭俊超,刘子文,张太平.胰腺癌阿霉素耐药细胞株SW1990/ADM的建立及其耐药机理研究[J].中国普外基础与临床杂志,2005,12(1):46-50. 被引量：15
-
3贺秋平,张春霞.小儿左旋门冬酰胺酶过敏反应的抢救与护理8例[J].中原医刊,2005,32(22):93-93. 被引量：4
-
4顾伟,张亚妮,李柏,韩洁,程彬彬,凌昌全.人肝癌BEL-7402/5-FU多药耐药细胞株的建立及其生物学特性观察[J].中西医结合学报,2006,4(3):265-270. 被引量：8
-
5张燕,孙雅红,徐从高.凋亡抑制因子与肿瘤耐药研究进展[J].国际肿瘤学杂志,2006,33(7):500-502. 被引量：4
-
6于亚平.门冬酰胺酶在急性淋巴细胞白血病治疗中的副作用及其对策[J].现代肿瘤医学,2007,15(1):119-123. 被引量：18
-
7徐巧元,张幸平.肿瘤多药耐药机制的研究进展[J].重庆医学,2007,36(14):1434-1436. 被引量：5
-
8GIOVANNI CC, FABRIZIO R, GAIN P, et al. Low-dose inter- leukin-2 administered pre-operatively topatients with gastric can- cer :tivates peripheral and perit-umoral, lymphocytes but does not affect prognosis[J]. Annals Surgical Oncology, 2007, 14(4): 1295-1304.
-
9TABATABAI G, WELLER M. Glioblastoma stem cells[J]. Cell Tissue Res, 2011, 343(3): 459-465.
-
10KO0 HM, MCWILLIAMS MJ, ALVORD WG, et al. Ras onco- geneinduced sensitization to 1-beta-D-arabinofuranosylcytosine[J]. Cancer Resarch, 1999, 59(24): 6057-6062.
二级引证文献6
-
1朱大诚,陈秀珍,范亚利,翁剑锋.白花蛇舌草水提物对白血病多药耐药细胞株CEM/VCR抑制作用的研究[J].时珍国医国药,2014,25(11):2619-2621. 被引量：6
-
2朱大诚,陈秀珍,何莲花.蟾酥对白血病多药耐药细胞株CEM/VCR抑制作用的研究[J].时珍国医国药,2015,26(7):1553-1556. 被引量：4
-
3孙维梅,李建厂,贾秀红,李有杰,唐慎华.siRNA沉默CDX2基因联合化疗药物对白血病K562细胞增殖、凋亡的影响[J].中国肿瘤生物治疗杂志,2016,23(2):218-222. 被引量：2
-
4朱大诚,陈甜甜,陈秀珍,肖威.蟾酥逆转白血病多药耐药细胞CEM/VCR的作用及其机制研究[J].时珍国医国药,2017,28(8):1819-1822. 被引量：5
-
5朱大诚,陈甜甜,陈秀珍,温伟接.蟾酥对白血病多药耐药细胞CEM/VCR逆转作用的研究[J].时珍国医国药,2018,29(4):772-775. 被引量：4
-
6刘燕,戴莉,黄倩,蔡力,肖李岩.培门冬酶治疗儿童急性淋巴细胞白血病的近期疗效及对患儿不良反应的影响[J].湖南师范大学学报（医学版）,2023,20(4):129-133.
-
1付凯.B细胞非霍奇金淋巴瘤的基因表达研究[J].中国肿瘤临床,2011,38(18):1061-1066. 被引量：1
-
2小肠[J].中国癌症防治杂志,1996(1):53-54.
-
3张公馥.原发性小肠肿瘤20例临床分析[J].实用癌症杂志,1995,10(2):127-129.
-
4江川,王强,汤宁文.原发性胃恶性淋巴瘤11例误诊分析[J].福建医药杂志,2003,25(6):74-74.
-
5张红.胃原发性恶性淋巴瘤的胃镜诊断[J].浙江预防医学,2006,18(2):70-70.
-
6步嵘,王耀平,林梓.儿童淋巴系统恶性肿瘤免疫分型与IgH、TCRγ基因重排关系的初步探讨[J].白血病,1999,8(2):71-74. 被引量：1
-
7孟昭升,盛玲玲,徐欣欣,关忠.左旋门冬酰胺酶治疗恶性血液病致出、凝血功能异常原因及防治对策[J].中国医师进修杂志,2012,35(22):73-75. 被引量：1
-
8姜文奇.非霍奇金淋巴瘤治疗研究新进展[J].继续医学教育,2007,21(4):19-23.
-
9侯明,冀学斌.非霍奇金淋巴瘤治疗的现状和未来[J].医师进修杂志,2003,26(12):1-3.
-
10聂玉玲,王晓敏.美罗华治疗弥漫性大B细胞淋巴瘤的研究进展[J].新疆医学,2008,38(2):105-109.
